Ruolo del CA 125 nelle masse pelviche: Nostra esperienza

Translated title of the contribution: CA 125 tumor marker screening rule: Our experience

M. Rotondi, C. Lauro, F. P. Ammaturo, V. Guerriero, M. Rasile, S. Panariello

Research output: Contribution to journalArticlepeer-review


Background. The goal of our study is to plan a screening program for early detection of ovarian cancer through clinical examination, pelvic ultrasonography and serum Ca 125 dosage. Methods. Between January 1993 and June 1999, 436 patients have been submitted to ovarian cancer screening at the Obstetrics and Gynecology Institute of the Second University of Naples. All women were in postmenopausal period, older than 50 years and didn't show any gynecologic disease. Results. Clinical examination selected 41 patients (9.4%) with a pelvic mass; pelvic ultrasonography revealed ovarian or uterine mass (only subserous myoma) in 87 cases (19.9%). These patients were submitted to Ca 125 serum dosage; in three cases Ca 125 was higher than 65 U/ml and in 26 cases its value was between 35 and 65 U/ml. The remaining 58 patients showed Ca 125 values lower than 35 U/ml. Four patients with ovarian cancer have been detected with our screening program. Conclusions. The authors conclude that pelvic ultrasonography and serum Ca 125 dosage are useful for the assessment of an early screening program of ovarian cancer.

Translated title of the contributionCA 125 tumor marker screening rule: Our experience
Original languageItalian
Pages (from-to)51-54
Number of pages4
JournalMinerva Ginecologica
Issue number1 SUPPL. 1
Publication statusPublished - Feb 2001

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'CA 125 tumor marker screening rule: Our experience'. Together they form a unique fingerprint.

Cite this